Invasive aspergillosis: A comprehensive review
Med Clin (Barc). 2024 Aug 30;163(4):189-198.
doi: 10.1016/j.medcli.2024.01.045.
Epub 2024 May 6.
[Article in
English,
Spanish]
Affiliations
- 1 Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Universidad de Alcalá, Escuela de Doctorado, Alcalá de Henares, Spain. Electronic address: marina.machado@salud.madrid.org.
- 2 Infectious Diseases Department, Hospital Ramón y Cajal, Madrid, Spain; Universidad de Alcalá, Escuela de Doctorado, Alcalá de Henares, Spain; IRYCIS: Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
- 3 Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias - CIBERES (CB06/06/0058), Madrid, Spain; Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid, Spain.
Abstract
Invasive aspergillosis (IA) is a severe fungal infection caused by Aspergillus species, particularly Aspergillus fumigatus, although new species, sometimes resistant to antifungals are becoming more common. IA predominantly affects immunocompromised patients, such as those with haematological malignancies, solid organ transplant recipients, and critically ill patients. However, new at-risk populations have emerged in recent years, such as IA associated with severe viral infections. Advanced diagnostic methods are crucial, especially considering the rising concern of antifungal resistance. Early detection is critical for successful treatment, typically involving antifungal medications like voriconazole or amphotericin B, but new antifungals are arriving to complete the therapeutic strategies. Despite advancements, mortality rates remain high, underscoring the importance of timely interventions and ongoing research. Healthcare providers should maintain a high index of suspicion, especially in immunocompromised patients and other new risk factors that are arising, to promptly diagnose and manage invasive aspergillosis.
Keywords:
Aspergillus fumigatus; Aspergilosis invasiva; Aspergilosis pulmonar; Infección fúngica invasiva; Invasive aspergillosis; Invasive fungal infections; Pulmonary aspergillosis.
Copyright © 2024 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antifungal Agents* / therapeutic use
-
Aspergillosis* / diagnosis
-
Aspergillosis* / drug therapy
-
Humans
-
Immunocompromised Host*
-
Invasive Fungal Infections / diagnosis
-
Invasive Fungal Infections / drug therapy
-
Risk Factors